Combined systemic and topical treatment of disordered tissues
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A01N-043/04
A61K-031/70
A61K-031/522
A61K-031/14
A61K-031/7072
A61K-031/52
A61K-031/662
A61K-031/675
A61K-031/7125
출원번호
US-0804002
(2013-03-14)
등록번호
US-9125911
(2015-09-08)
발명자
/ 주소
Johnson, B. Ron
출원인 / 주소
QUADEX PHARMACEUTICALS, LLC
대리인 / 주소
Workman Nydegger
인용정보
피인용 횟수 :
2인용 특허 :
115
초록▼
Kits and methods for treating disordered tissue caused by a virus in a mammal involve co-administration of a systemic anti-virus drug and topically administering an anti-infective composition. The systemic anti-virus drug is internally administered and disrupts or inhibits virus replication systemic
Kits and methods for treating disordered tissue caused by a virus in a mammal involve co-administration of a systemic anti-virus drug and topically administering an anti-infective composition. The systemic anti-virus drug is internally administered and disrupts or inhibits virus replication systemically within the mammal. Examples include nucleoside analogues, nucleoside analogue precursors, and nucleotide analogues. The topically administered anti-infective composition includes at least one anti-infective agent, such as an organohalide (e.g., benzalkonium chloride), and is formulated to penetrate below the disordered tissue surface and allow the anti-infective agent to kill viruses at the disordered tissue site. The anti-infective composition reduces the time and/or number of dosages required for the systemic anti-virus drug to treat the disordered tissue in the absence of topically administering the anti-infective composition. It also reduces or eliminates incidences of post-treatment neuralgia.
대표청구항▼
1. A method of treating disordered tissue caused by a virus in a mammal, comprising: administering an effective amount of a systemic anti-virus drug to a mammal in need thereof in order to disrupt or inhibit virus replication systemically within the mammal, wherein the systemic anti-virus drug is se
1. A method of treating disordered tissue caused by a virus in a mammal, comprising: administering an effective amount of a systemic anti-virus drug to a mammal in need thereof in order to disrupt or inhibit virus replication systemically within the mammal, wherein the systemic anti-virus drug is selected from the group consisting of acyclovir, valaciclovir, penciclovir, famciclovir, ganciclovir, cidofovir, adefovir, tenofovir, and combinations thereof; andtopically administering an anti-infective composition comprising at least one anti-infective agent to the disordered tissue of the mammal in order for the composition to penetrate below the disordered tissue surface and independently kill viruses at the disordered tissue site, wherein the at least one anti-infective agent comprises benzalkonium chloride. 2. A method as in claim 1, wherein the anti-infective composition further comprises a liquid carrier having a tissue penetrating component. 3. A method as in claim 2, wherein the tissue penetrating component comprises a lower alkyl solvent and water. 4. A method as in claim 3, wherein the lower alkyl solvent comprises at least one of isopropyl alcohol, ethyl alcohol, or acetone. 5. A method as in claim 2, wherein the anti-infective composition is free of oils or other compounds that inhibit penetration. 6. A method as in claim 1, wherein the method comprises administering a plurality of dosages of the systemic anti-virus drug periodically over a prescribed period of time. 7. A method as in claim 6, wherein topically administering the anti-infective composition reduces the time and/or number of dosages of the systemic anti-virus drug required to treat the disordered tissue and promote healing of one or more lesions at the disordered tissue site compared to treating the disordered tissue using the anti-virus drug by itself in the absence of topically administering the anti-infective composition to the disordered tissue. 8. A method as in claim 7, wherein topically administering the anti-infective composition reduces the time and/or number of dosages of the systemic anti-virus drug required to treat the disordered tissue and promote healing of one or more lesions at the disordered tissue site by at least about 10% compared to treatment of the disordered tissue and healing of the one or more lesions using the anti-virus drug by itself in the absence of topically administering the anti-infective composition to the disordered tissue. 9. A method as in claim 7, wherein topically administering the anti-infective composition reduces the time and/or number of dosages of the systemic anti-virus drug required to treat the disordered tissue and promote healing of one or more lesions at the disordered tissue site by at least about 20% compared to treatment of the disordered tissue using the anti-virus drug by itself in the absence of topically administering the anti-infective composition to the disordered tissue. 10. A method as in claim 7, wherein topically administering the anti-infective composition reduces the time and/or number of dosages of the systemic anti-virus drug required to treat the disordered tissue and promote healing of one or more lesions at the disordered tissue site by at least about 30% compared to treatment of the disordered tissue using the anti-virus drug by itself in the absence of topically administering the anti-infective composition to the disordered tissue. 11. A method as in claim 7, wherein topically administering the anti-infective composition reduces or eliminates the incidence of post treatment neuralgia compared to when treating the disordered tissue using the anti-virus drug by itself in the absence of topically administering the anti-infective composition to the disordered tissue. 12. A method as in claim 7, wherein the method comprises topically administering 5 dosages or less of the anti-infective composition throughout the entire treatment process. 13. A method as in claim 7, wherein the method comprises topically administering 3 dosages or less of the anti-infective composition throughout the entire treatment process. 14. A method as in claim 7, wherein the method comprises topically administering a single dosage of the anti-infective composition throughout the entire treatment process. 15. A method as in claim 1, wherein at least one dose of the systemic anti-virus drug and the anti-infective composition are administered substantially simultaneously. 16. A method as in claim 1, wherein at least one dose of the systemic anti-virus drug and the anti-infective composition are administered within 2 hours of each other. 17. A method as in claim 1, wherein at least one dose of the systemic anti-virus drug and the anti-infective composition are administered within 12 hours of each other. 18. A method as in claim 1, wherein at least one dose of the systemic anti-virus drug and the anti-infective composition are administered within 1 day of each other. 19. A method as in claim 1, wherein the anti-infective composition further comprises at least one topical anesthetic. 20. A method as in claim 19, wherein the at least one topical anesthetic is included in an amount so as to enhance efficacy of the anti-infective composition in treating the disordered tissue and accelerate healing of the disordered tissue. 21. A method as in claim 19, wherein the at least one topical anesthetic is selected from the group consisting of benzocaine, butamben, dibucaine, lidocaine, oxybuprocaine, pramoxine, proparacaine, proxymetacaine, novocaine, tetracaine, and combinations thereof. 22. A method of treating disordered tissue caused by a virus in a mammal, comprising: systemically administering a pharmaceutically effective amount of an anti-virus drug to a mammal in need thereof in order to disrupt or inhibit virus replication systemically within the mammal, wherein the anti-virus drug comprises at least one of acyclovir, valaciclovir, penciclovir, famciclovir, ganciclovir, cidofovir, adefovir,or tenofovir; andtopically administering an anti-infective composition comprising at least one anti-infective agent to a lesion at a disordered tissue site of the mammal in order for the anti-infective composition to penetrate below a surface of the lesion without rapidly diffusing beyond the skin and into the bloodstream and kill or deactivate viruses at the disordered tissue site, wherein the anti-infective composition comprises benzalkonium chloride and a tissue penetrating liquid carrier,wherein topically administering the anti-infective composition reduces the time and/or number of dosages of the systemic anti-virus drug required to treat the disordered tissue and promote healing of the lesion by at least about 10% compared to treatment of the disordered tissue using the anti-virus drug by itself in the absence of topically administering the anti-infective composition to the disordered tissue. 23. A method as in claim 22, wherein topically administering the anti-infective composition reduces or eliminates the incidence of post treatment neuralgia compared to when treating the disordered tissue using the anti-virus drug by itself in the absence of topically administering the anti-infective composition to the lesion.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (115)
Gern James E. ; Mosser Anne G., Acidic buffered nasal spray.
Kimberly Ann Biedermann ; Jeffrey Michael Morgan ; Karl Shiqing Wei ; Mark Richard Sine GB; Cheyne P. Thomas ; David Edmund Tarantino ; Christopher Irwin ; Christopher Dean Putman ; Peter Wil, Antimicrobial cleansing compositions containing 2-pyrrolidone-5-carboxylic acid.
Gorman William G. (East Greenbush NY) Popp Karl F. (Schodack Landing NY), Basic amino or ammonium antimicrobial agent-polyethylene glycol ester surfactant-betaine and/or amine oxide surfactant c.
Donofrio Deborah K. (The Woodlands TX) Whitekettle Wilson K. (Conroe TX), Biocidal compositions and use thereof containing a synergistic mixute of 2-(decylthio)ethanamine hydrochloride and n-alk.
Swered Paul (Philadelphia PA) Donofrio Deborah K. (The Woodlands TX), Biocidal compositions and use thereof employing a synergistic mixture of n-alkyldimethyl benzyl ammonium halide and n-do.
Dalrymple Damon M. ; Manning Monna ; Merz Frank,DEX, Clear personal care formulations containing quaternary ammonium compounds and other nitrogen-containing compounds.
Dalrymple, Damon M.; Manning, Mona; Merz, Frank, Clear personal care formulations containing quaternary ammonium compounds and other nitrogen-containing compounds.
Balzarini Jan M. R. (Heverlee BEX) De Clercq Erik D. A. (Heverlee BEX), Combinations of TS-inhibitors and viral TK-inhibitors in antiherpetic medicines.
Bergeron Michel G.,CAX ; Desormeaux Andre,CAX ; Tremblay Michel,CAX, Formulation for use in the prevention of pathogen induced diseases including HIV and HSV.
Drube Clairmont G. (Green Valley AZ), Method for medicating the inflammatory controlling system and adverse inflammatory reactions and for making compounds fo.
Simmons Paul L. (6250 Kipps Colony Ct. ; No. 203 Gulfport FL 33707) Immekus Robert L. (106 E. Hanna Ave. Tampa FL 33604), Method of immersion sterilization and organic cold chemical sterilant.
Stalcup Robert W. (21152 Pepopertree La. Mission Viejo CA 92691) McCall Robert G. (7468 E. Raintree Ct. Scottsdale AZ 85258), Method of providing topoical anesthetic in a sanitary and convenient manner.
Bourbon Pierre (Toulouse FRX) Lagny Pierre (Clebridge IEX) Billot Pierre (Neuilly Sur Seine FRX), Method which inhibits or destroys at least one unicellular living organism containing a quaternary ammonium fluoride.
Stevens Kent R. (Chatam NJ) Taggart William V. (Quakertown NJ), Polyamides bearing functionalized side chains useful as water soluble hypolipidemic agents.
Bollen Alex (Gaasbeekstraat 65 Brussels BEX) Moguilevsky Nicle (4 rue P. Delacroix Brussels B-1150 BEX) Pourtois Michel (23 avenue de la Floride Brussels BEX), Prophylactic and therapeutic applications of peroxidases.
Sheldon Bernard G. (Palo Alto CA) Wingard ; Jr. Robert E. (Mountain View CA) Weinshenker Ned M. (Palo Alto CA) Dawson Daniel J. (Los Altos CA), Quaternary ammonium group-containing polymers having antimicrobial activity.
Brown-Skrobot Susan K. (Hamilton Square NJ) Hossain Shafi U. (Roswell GA) Smith Kenneth R. (Marietta GA) Kuenn Cary K. (Appleton WI), Virucidal composition, the method of use and the product therefor.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.